黑色素受体激活剂与帕金森病之间的关系
Yoshihiro Noguchi1, Rikuto Masuda1, Haruka Aizawa1
1Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
Journal of pineal research
|August 9, 2024
概括
拉梅尔和塔西梅尔与帕金森病风险有负面关联. 然而,阿戈梅拉丁显示出正相关性,这表明黑激素受体激动剂对帕金森病的差异效应.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 帕金森病 (PD) 影响全球数以百万计的人,预计发病率和流行率将增加.
- 针对睡眠和昼夜节律的新型治疗策略正在对PD进行研究.
- 黑色素受体激活剂代表着一种潜在的药物类别,可以影响这些系统.
研究的目的:
- 为了研究特定的黑激素受体激动剂与帕金森病之间的关联.
- 评估Ramelteon,Tasimelteon和Agomelatine与PD有关的安全性和潜在的差异性影响.
主要方法:
- 使用了食品和药物管理局 (FDA) 的不良事件报告系统 (FAERS) 数据库.
- 使用标准化MedDRA查询 (SMQ) 定义了帕金森病病例,使用狭窄和广泛的首选术语.
- 计算了报告几率比率 (ROR) 来评估药物暴露与PD诊断之间的关联.
主要成果:
- 拉梅尔顿与帕金森病有负相关性 (ROR:0.66,95%CI:0.51-0.84).
- 塔西梅尔顿还显示与帕金森病的负相关性 (ROR:0.49,95% CI:0.38-0.62).
- 阿戈梅拉丁与帕金森病具有积极的相关性 (ROR:2.63,95% CI:2.04-3.40).
结论:
- 拉梅尔和塔西梅尔似乎与帕金森病有着保护性的关联.
- 阿戈梅拉丁可能与帕金森病的风险增加有关.
- 这些发现突出了对治疗PD的黑激素受体激动剂的进一步研究的需要,考虑到药物特异性影响和报告系统的局限性.
相关概念视频
01:24Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
01:19Management of Insomnia
237
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
237
01:15Parkinson's Disease: Overview
508
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
508
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
163
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
163
01:25Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K